Skip to content
2000
Volume 17, Issue 5
  • ISSN: 1573-4129
  • E-ISSN: 1875-676X

Abstract

Background: Danyikangtai powder, a Traditional Chinese Medicine (TCM) formula, shows promise to become a novel drug candidate for the simultaneous treatment of chronic cholecystitis and chronic pancreatitis. However, the pharmacokinetic behavior of Danyikangtai powder remains unclear. Objective: We investigated the comparative pharmacokinetics of four flavonoids in rats after oral administration of Danyikangtai powder and three compatibilities. Materials and Methods: The comparative pharmacokinetics was studied by ultra-performance liquid chromatography-tandem mass spectrometry (UPLC–MS/MS). Chromatographic separation was performed on a Universil XB-C18 column with a gradient mobile phase containing 0.1% (v/v) aqueous formic acid and acetonitrile. All analytes and internal standard were quantitated in the multiple reaction monitoring modes with a positive electrospray ionization interface. Results and Discussion: Danyikangtai powder and Scutellariae radix have similar pharmacokinetic behaviors in rats after oral administration. However, the elimination of four flavonoids in rats after oral administration of Danyikangtai powder was accelerated, which was possibly related to the reduction of the potential hepatotoxicity of Scutellariae radix. The varying degrees of change in pharmacokinetic parameters after oral administration of different herb combinations suggested that herb–herb interactions occurred in vivo. Conclusion: This study will be helpful to reveal the safety, rational and mechanism of Danyikangtai powder formula compatibility, thereby providing pre-clinical research data for its new drug development and guidance for its rational clinical application.

Loading

Article metrics loading...

/content/journals/cpa/10.2174/1573412916666200130112247
2021-06-01
2025-12-07
Loading full text...

Full text loading...

/content/journals/cpa/10.2174/1573412916666200130112247
Loading
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test